ReviewBritish journal of haematology2025
T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.
Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma metabolomics profile alterations in the onset and progression of paediatric immune thrombocytopenia.British journal of haematology · 2026Article
- MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.British journal of haematology · 2026Review
- T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.British journal of haematology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease where premature destruction of platelets as well as inhibition of platelet production leads to thrombocytopenia and associated bleeding. It has long been considered a disease primarily caused by B cells, but the role of T lymphocytes in its pathogenesis is now better understood and deserves elucidation. Two types of T cells will be discussed: (1) splenic T follicular helper cells (TFH) that participate in differentiation of B cells within germinal centres (GC) and stimulate the production of antiplatelet antibodies, thus supporting the humoral autoimmune response; and (2) antibody-independent mechanisms of action of cytotoxic T lymphocytes (CTL) that may directly participate in platelet destruction as well as inhibit their production by targeting megakaryocytes. To date, most novel therapies target antibody-mediated disease, but targeting either TFH or CTL may provide new therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.